APRE
Aprea Therapeutics, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website aprea.com
- Employees(FY) 9
- ISIN US03836J2015
Performance
-4.18%
1W
-9.91%
1M
-9.57%
3M
+40.53%
6M
+12.13%
YTD
+37.24%
1Y
Profile
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Technical Analysis of APRE 2024-05-10
Overview:
In analyzing the technical indicators for APRE over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the c...
Recent News & Updates
- 2024-05-14 01:53
- 2024-05-13 20:30
- 2024-05-13 04:01
- 2024-05-01 21:15
- 2024-04-10 00:00
- 2024-03-26 01:53
- 2024-03-25 19:45
- 2024-03-10 20:30
- 2024-03-10 20:29
- 2024-03-05 03:45
- 2024-02-05 19:01
- 2024-01-29 19:00
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024(Globenewswire)
- 2024-01-04 03:05
- 2023-11-09 03:05
- 2023-10-23 20:00
- 2023-10-15 20:30
- 2023-09-18 20:00
- 2023-09-10 20:00
- 2023-09-06 04:05
- 2023-08-23 19:30
- 2023-08-09 19:30
- 2023-06-13 20:00
- 2023-05-29 20:30
- 2023-05-15 04:05
- 2023-05-07 20:00
- 2023-04-23 21:55
- 2023-04-04 00:00
- 2023-03-30 04:05
- 2023-03-15 20:00
- 2023-03-06 19:00
Page 1 of 4
previousnext